These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 19650753

  • 1. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.
    LaForce C, Korenblat P, Osborne P, Dong F, Higgins M.
    Curr Med Res Opin; 2009 Oct; 25(10):2353-9. PubMed ID: 19650753
    [Abstract] [Full Text] [Related]

  • 2. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
    Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M.
    Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.
    Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S.
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [Abstract] [Full Text] [Related]

  • 6. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M.
    Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.
    Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M.
    J Asthma; 2008 Dec; 45(10):887-92. PubMed ID: 19085578
    [Abstract] [Full Text] [Related]

  • 8. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I, Hall IP, McFarlane LC, Lipworth BJ.
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Mar; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 16. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F.
    Pneumologia; 2011 Mar; 60(1):21-5. PubMed ID: 21548196
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.